Home/Filings/4/0001104659-24-035619
4//SEC Filing

Piccina Cintia 4

Accession 0001104659-24-035619

CIK 0001621227other

Filed

Mar 17, 8:00 PM ET

Accepted

Mar 18, 5:00 PM ET

Size

8.9 KB

Accession

0001104659-24-035619

Insider Transaction Report

Form 4
Period: 2024-03-18
Piccina Cintia
Chief Commercial Officer
Transactions
  • Award

    Option to purchase Ordinary Shares

    2024-03-18+5,088,8645,088,864 total
    Exercise: $0.25Exp: 2034-03-18Ordinary Shares (5,088,864 underlying)
  • Award

    Option to purchase Ordinary Shares

    2024-03-18+1,130,8321,130,832 total
    Exercise: $0.00Ordinary Shares (1,130,832 underlying)
Footnotes (5)
  • [F1]The exercise price was converted from GBP0.19 based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F2]Exercisable as to 1,679,325 Ordinary Shares on March 18, 2024 and will be exercisable as to the remainder in monthly installments of 94,704 Ordinary Shares on the last day of each month from April 18, 2024 through February 18, 2027 and 94,899 Ordinary Shares on March 18, 2027.
  • [F3]The exercise price was converted from GBP0.001, being the nominal value of an ordinary share, based on an exchange rate of $U.S. 1.273980 to GBP1.00. The actual exercise price will be the pounds sterling amount.
  • [F4]Exercisable as to 376,944 Ordinary Shares on June 18, 2024 and will be exercisable as to the remainder in installments of 188,472 Ordinary Shares on January 15, 2025, January 15, 2026, January 15, 2027 and January 15, 2028.
  • [F5]The expiration date of each annual installment of ordinary shares is March 15 of the calendar year following the year in which that installment becomes exercisable.

Issuer

Adaptimmune Therapeutics PLC

CIK 0001621227

Entity typeother

Related Parties

1
  • filerCIK 0001907199

Filing Metadata

Form type
4
Filed
Mar 17, 8:00 PM ET
Accepted
Mar 18, 5:00 PM ET
Size
8.9 KB